

Figure 1. Use of peptides and IFN- γ ELISPOT to identify pathogenic CD4 T lymphocytes




Figure 2. Use of peptides and IL-10 ELISPOT to identify protective CD4 T lymphocytes




Figure 3. Use of peptides and IFN- γ and IL-10 ELISPOT to identify pathogenic and protective CD4 T lymphocytes in a single assay format




Figure 4. Evidence that anti-inflammatory IL-10 producing CD4+ T lymphocytes that respond to IA-2 and PI peptides delay diabetes onset.

